Physician profile
Paul Conley
NPI 1578550141
$13,795.54
in general payments reported to CMS, 2019-2025
34 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,553 · 2020: $2,220 · 2021: $1,808 · 2022: $2,029 · 2023: $1,674 · 2024: $1,058 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,185.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,567.07 | 2019-2025 | Xifaxan, Relistor, Uceris |
| Abbvie INC. | $3,178.21 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $852.89 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Novo Nordisk INC | $574.55 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $485.38 | 2019-2022 | |
| Genzyme Corporation | $468.63 | 2022-2025 | |
| Pfizer INC. | $405.75 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $328.46 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $295.13 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $230.31 | 2025 | Vegzelma, Zymfentra |
| Janssen Pharmaceuticals, INC | $187.70 | 2019 | |
| Ardelyx, INC. | $154.67 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $153.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $147.17 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $144.21 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $133.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.82 | 2019-2020 | |
| Amarin Pharma, INC. | $124.52 | 2019-2022 | |
| Ucb, INC. | $122.29 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $121.93 | 2020 | |
| Boston Scientific Corporation | $114.70 | 2019-2020 | |
| Madrigal Pharmaceuticals | $114.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $101.72 | 2020-2023 | |
| Celgene Corporation | $97.09 | 2021-2023 | Zeposia |
| Sanofi-Aventis U.S. LLC | $95.76 | 2019-2020 | |
| Redhill Biopharma INC. | $90.67 | 2020-2021 | |
| Amgen INC. | $89.09 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $87.77 | 2025 | Iqirvo |
| Allergan, INC. | $70.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $41.89 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $40.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2020 | |
| Shionogi INC | $15.11 | 2019 | |
| Merck Sharp & Dohme LLC | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.